Vyne Therapeutics Inc (VYNE) — Cash Flow-to-Debt Ratio
Vyne Therapeutics Inc (VYNE) has a Cash Flow-to-Debt Ratio of -1.57x as of December 2025, meaning its operating cash flow of $-3.76 Million could theoretically repay -2% of its total liabilities ($2.40 Million) in one year. See Vyne Therapeutics Inc (VYNE) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vyne Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Vyne Therapeutics Inc across 11 annual periods. Also explore Vyne Therapeutics Inc (VYNE) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Vyne Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Vyne Therapeutics Inc. For market capitalisation and broader financial context, see market value of Vyne Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -13.83x | $-33.12 Million | $2.40 Million | ▼ -503.3% |
| 2024 | -2.29x | $-33.97 Million | $14.82 Million | ▲ +19.0% |
| 2023 | -2.83x | $-25.34 Million | $8.95 Million | ▲ +7.3% |
| 2022 | -3.06x | $-29.20 Million | $9.56 Million | ▲ +0.2% |
| 2021 | -3.06x | $-56.37 Million | $18.41 Million | ▼ -25.6% |
| 2020 | -2.44x | $-137.08 Million | $56.25 Million | ▲ +60.1% |
| 2019 | -6.11x | $-65.10 Million | $10.66 Million | ▼ -10.6% |
| 2018 | -5.52x | $-52.73 Million | $9.55 Million | ▼ -2321.8% |
| 2017 | -0.23x | $-28.25 Million | $123.90 Million | ▼ -611.4% |
| 2016 | -0.03x | $-2.29 Million | $71.49 Million | ▲ +54.2% |
| 2015 | -0.07x | $-4.18 Million | $59.84 Million | — |